Amlodipine generally lowers blood pressure more than losartan when the two drugs go head to head, but “better” depends on more than just the number on a cuff. In a direct comparison trial of patients with mild to moderate hypertension, amlodipine reduced systolic pressure by about 16 mm Hg versus roughly 14 mm Hg for losartan, and the gap in diastolic reduction was similarly in amlodipine’s favor. Yet losartan offers distinct advantages for kidney protection, uric acid control, and heart-muscle remodeling that make it the stronger choice for certain patients. Picking between these two drugs is less about declaring a winner and more about matching the medication to the person taking it.
How the Two Drugs Lower Blood Pressure
Amlodipine is a calcium channel blocker. It works on the smooth muscle cells lining your arteries by blocking calcium from entering those cells, which prevents the muscle from contracting as forcefully. The result is wider, more relaxed blood vessels and lower pressure. Research on isolated vascular smooth muscle cells confirmed that amlodipine inhibits calcium channel currents in a dose-dependent way, and there is additional evidence that it has pharmacologic actions beyond simple calcium channel blockade that may contribute to vascular protection.1PubMed Central. The action of amlodipine on voltage-operated calcium channels in vascular smooth muscle2PubMed. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine
Losartan takes a completely different route. It blocks the receptor for angiotensin II, a hormone that tells blood vessels to tighten and signals the body to retain salt and water. By sitting on that receptor and preventing angiotensin II from binding, losartan relaxes vessels and reduces fluid volume. It was the first drug in this class, known as angiotensin receptor blockers, to reach the market for hypertension.3Current Therapeutic Research. Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension
These different mechanisms matter because they create different side-effect profiles, different organ-protective effects, and different responses in different patients. Two drugs that both lower blood pressure can still be worlds apart in practice.
Head-to-Head Blood Pressure Reduction
The most cited direct comparison found that amlodipine outperformed losartan on both systolic and diastolic readings. Patients on amlodipine saw diastolic pressure drop by about 13 mm Hg compared with about 10 mm Hg for losartan, and systolic pressure fell by about 16 mm Hg versus roughly 14 mm Hg. Both differences were statistically meaningful. The study also looked at what happened when patients who didn’t reach their goal on the starting dose were stepped up: losartan patients had a diuretic added, while amlodipine patients got a higher dose. Even after that adjustment, amlodipine-treated patients were more likely to hit their blood pressure target.4PubMed Central. The effects of amlodipine compared to losartan in patients with mild to moderately severe hypertension
A separate trial comparing the two drugs’ effects around the clock found a similar pattern. Averaged over 24 hours, systolic blood pressure was significantly lower in the amlodipine group. During daytime hours the two drugs performed comparably, but amlodipine pulled ahead in the evening and early morning. Evening systolic readings averaged about 133 mm Hg on amlodipine versus 138 mm Hg on losartan, and morning readings were roughly 129 versus 134 mm Hg. The trough-to-peak ratio, a measure of how well a drug’s effect persists until the next dose, was also higher with amlodipine.5PubMed. Comparison of the effects of amlodipine and losartan on 24-hour ambulatory blood pressure in hypertensive patients
If pure pressure-lowering power is all you care about, amlodipine has a consistent edge. But blood pressure numbers on their own don’t tell the whole story of cardiovascular risk.
Side Effects People Actually Notice
The most common complaint with amlodipine is ankle and lower-leg swelling. This is not a sign of heart failure or kidney problems; it happens because the drug dilates the small arteries feeding the legs without equally dilating the veins draining them, creating an imbalance in pressure that pushes fluid into surrounding tissue.6PubMed Central. Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: A systematic review and network meta-analysis In one trial directly comparing the two drugs, swelling or edema was reported by about 10% of amlodipine patients versus 3% of losartan patients.7Current Therapeutic Research. Efficacy, safety, and effects on hypertension-associated symptoms of losartan, alone or in combination with hydrochlorothiazide, versus amlodipine in patients with mild-to-moderate hypertension
Losartan is generally well tolerated. Some people experience dizziness, especially when starting. Unlike ACE inhibitors, the closely related drug class, losartan rarely causes the persistent dry cough that drives many patients to switch medications. This tolerability advantage shows up in long-term adherence data: in a four-year tracking study, a greater proportion of losartan patients stayed on their medication compared with patients started on calcium channel blockers. At 12 months, about 67% of losartan patients remained on therapy versus roughly 54% of calcium channel blocker patients, and the gap persisted out to 48 months.8Clinical Therapeutics. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes
Persistence matters enormously for a condition that requires daily medication for years or decades. A drug that works slightly better on paper is useless if the patient stops taking it because of puffy ankles.
The Uric Acid Advantage
Losartan has a metabolic trick that no other drug in its class shares: it lowers uric acid. High uric acid is the driver behind gout, a painful form of arthritis, and is also linked to cardiovascular risk. Losartan promotes uric acid excretion through the kidneys by a mechanism unrelated to its blood-pressure-lowering action. Studies in healthy volunteers and hypertensive patients have shown uric acid drops of about 20 to 25%, an effect comparable to classic uric-acid-lowering medications.9BMJ. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study Other angiotensin receptor blockers do not do this, so the benefit is specific to losartan.
When losartan was combined with amlodipine in one study, uric acid levels fell from an average of 6.5 to 4.6 mg/dL, a steep decline. In a comparison group receiving losartan plus a diuretic instead, uric acid barely budged.10PubMed Central. Effect of losartan combined with amlodipine or with a thiazide on uric acid levels in hypertensive patients A separate study confirmed that switching patients from other angiotensin receptor blockers to losartan reduced uric acid even when a diuretic (which normally raises uric acid) was part of the regimen.11PubMed. Effect of losartan on serum uric acid in hypertension treated with a diuretic: the COMFORT study
For anyone with hypertension and a history of gout or elevated uric acid, losartan addresses two problems with a single pill. That is a meaningful real-world advantage that never shows up in a standard blood pressure comparison.
Kidney Protection in Diabetes
One of the sharpest differences between these two drugs emerges in patients with type 2 diabetes. Losartan reduces the amount of protein spilling into the urine, a sign of kidney damage, while amlodipine does not. In a prospective trial of hypertensive Japanese patients with diabetes, losartan cut urinary albumin excretion by about 24% over three months. Amlodipine-treated patients, by contrast, saw a slight increase in albumin excretion over the same period, and the difference between the groups was statistically significant.12Current Therapeutic Research. Anti-albuminuric effect of losartan versus amlodipine in hypertensive Japanese patients with type 2 diabetes mellitus: A prospective, open-label, randomized, comparative study
This kidney-protective effect is not unique to losartan; the entire class of angiotensin receptor blockers and ACE inhibitors is recommended for diabetic kidney disease. The mechanism involves reducing pressure inside the kidney’s filtration units by relaxing the outflow vessel. Amlodipine lowers overall blood pressure but does not selectively reduce that intra-kidney pressure, which is why it can lower your cuff reading without protecting the kidneys the same way. For patients with diabetes or early signs of kidney disease, this distinction frequently tips the prescribing decision toward losartan or a similar drug.
Heart Muscle Remodeling
When blood pressure stays elevated for years, the heart’s main pumping chamber thickens to compensate. This thickening, called left ventricular hypertrophy, is itself a risk factor for heart failure and sudden cardiac death. Both amlodipine and losartan can reverse it, but losartan appears to do so more effectively. In a randomized trial of diabetic patients with hypertension, losartan reduced a standard measure of heart-muscle mass by about 19%, while amlodipine reduced it by about 10%, even though both drugs lowered blood pressure to a similar degree. The researchers attributed losartan’s larger effect to greater reduction in fibrosis within the heart muscle.13PubMed. Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial
A separate clinical study found consistent results, with losartan reducing the mass index by about 14 g/m² compared with about 12 g/m² for amlodipine over six to eight months of treatment.14Asian Journal of Pharmaceutical and Clinical Research. Assesment of Clinical Effectiveness of Losartan and Amlodipine in Hypertensive Patient with Left Ventricular Hypertrophy The difference in that study was smaller, but the direction was consistent. If you already have signs of heart-muscle thickening on an echocardiogram, losartan’s ability to address fibrosis gives it a theoretical leg up beyond simple pressure reduction.
Stroke and Heart Attack Prevention
Here the picture flips. A quantitative overview of multiple large trials found that amlodipine provided greater protection against stroke and heart attack than angiotensin receptor blockers as a class. Compared with ARBs, amlodipine-based regimens were associated with about 19% fewer strokes and about 7% fewer heart attacks. When ARB trials were pooled separately, there was actually a signal of increased stroke and heart attack compared with amlodipine-based regimens in head-to-head comparisons.15PubMed. Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview
This is one of the more counterintuitive findings in hypertension research. Losartan looks better on paper for organ protection in specific settings, yet when you zoom out to population-level event rates, amlodipine-based treatment is associated with fewer of the hard outcomes people care about most. Part of the explanation may be amlodipine’s stronger and more sustained blood pressure lowering, since even small average differences in pressure translate into large differences in event rates across millions of patients. There is also animal research suggesting losartan may have unique prehypertensive benefits on stroke risk in certain genetic models, but that work was in specially bred rats, not in humans, and is too preliminary to guide prescribing.16PubMed. Prehypertensive treatment with losartan, however not amlodipine, leads to long-term effects on blood pressure and reduces the risk of stroke in spontaneously hypertensive stroke-prone rats
Combining the Two
Because amlodipine and losartan lower blood pressure through entirely different pathways, using them together tends to produce additive effects. An eight-week randomized factorial trial tested various dose combinations and found that the combination therapies reduced diastolic blood pressure significantly more than either drug alone at most dose pairings.17PubMed. Evaluation of the dose-response relationship of amlodipine and losartan combination in patients with essential hypertension: an 8-week, randomized, double-blind, factorial, phase II, multicenter study
The combination also addresses amlodipine’s biggest side effect. The ankle swelling caused by calcium channel blockers improves when you add an angiotensin receptor blocker, because the ARB dilates the postcapillary veins that the calcium channel blocker leaves constricted, restoring the balance of pressure across the capillary bed. In pharmacokinetic studies, the two drugs did not interact in any clinically worrying way. Amlodipine modestly increased losartan’s clearance, but the effect was small enough that researchers considered the combination tolerable without dose adjustment.18Basic & Clinical Pharmacology & Toxicology. Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings
When the two are combined, there is an added benefit for arterial stiffness. A study comparing losartan plus amlodipine against losartan plus a thiazide diuretic found that the amlodipine combination produced smoother 24-hour central blood pressure control and a greater reduction in aortic pulse wave velocity, a marker of how stiff your large arteries are.19PubMed Central. The association of smoothness index of central blood pressure with ambulatory carotid femoral pulse wave velocity after 20-week treatment with losartan in combination with amlodipine versus hydrochlorothiazide For many patients whose blood pressure is not controlled on a single drug, the combination of both drugs may be the right answer rather than choosing one over the other.
Cost and Accessibility
Both drugs are available as generics, which makes them affordable compared with newer branded medications. Still, costs differ. A pharmacoeconomic analysis from India found that the cost of lowering blood pressure by one mm Hg was roughly half as much with amlodipine as with losartan.20International Journal of Basic & Clinical Pharmacology. Pharmacoeconomic comparison of losartan and amlodipine in patients of hypertension in a tertiary care teaching hospital A cost-effectiveness analysis from China comparing amlodipine with ARBs for stroke and heart attack prevention reached a similar conclusion, finding amlodipine to be both less expensive and associated with slightly better quality-adjusted outcomes.21Value in Health Regional Issues. A Cost-Effectiveness Analysis between Amlodipine and Angiotensin II Receptor Blockers in Stroke and Myocardial Infarction Prevention among Hypertension Patients in China
These analyses are strongly shaped by local drug pricing and healthcare infrastructure, so the numbers will differ from country to country. In the United States, generic versions of both drugs are widely available for only a few dollars a month. Cost becomes a more decisive factor in low- and middle-income settings, where even small price differences multiply across populations.
Older Adults and Fall Risk
One practical consideration that rarely makes it into the “which drug is better” conversation is fall risk. Data from the large ALLHAT trial showed that amlodipine was associated with a higher short-term risk of falls compared with both a diuretic and an ACE inhibitor in older adults. The hazard ratio was over 2 for falls in the amlodipine group compared with each of the other drugs in the early treatment period.22PubMed Central. The Effects of Antihypertensive Class on Falls, Syncope, and Orthostatic Hypotension in Older Adults: the ALLHAT Trial This association was short-term and did not extend to syncope or sustained orthostatic hypotension, but for a frail 80-year-old, even a brief period of increased fall risk is worth taking seriously.
Losartan does not carry the same signal for falls, which may be another reason it shows up favorably in adherence data for older patients. If you are helping an elderly family member manage their medications, this is a reasonable point to raise with their prescriber, especially during the first weeks of starting or increasing a dose.
When Dosing Timing Matters
Amlodipine has a long half-life, so it stays active in the body for well over a day. Even so, the time of day you take it can influence how your blood pressure behaves overnight. A study comparing morning versus evening amlodipine dosing found that morning dosing produced a more favorable 24-hour blood pressure pattern, with a greater nighttime dip in pressure and lower nighttime blood pressure burden.23PubMed. Differential effects of morning or evening dosing of amlodipine on circadian blood pressure and heart rate Evening dosing, counterintuitively, was associated with higher nighttime pressure load.
Losartan’s half-life is shorter, which partly explains why its blood pressure effect wanes more before the next dose. Some clinicians prescribe losartan twice daily, or pair it with a longer-acting ARB or a second agent, to cover the full 24 hours. There is less published chronotherapy data specifically for losartan, but the general principle with shorter-acting drugs is that matching the dose to the time of day when your pressure tends to be highest can improve control. For most people, the practical advice is straightforward: take your medication at the same time every day, and if your doctor specifically recommends morning dosing, there is a physiological reason behind it.
Deciding Between Them
There is no universal answer to which drug is “better.” The choice hinges on a handful of clinical questions your doctor should be weighing:
- Diabetes or kidney disease: Losartan’s ability to reduce protein in the urine gives it a strong edge.
- Gout or high uric acid: Losartan is the only ARB that actively lowers uric acid, making it a two-for-one option.
- Heart-muscle thickening: Losartan reverses left ventricular hypertrophy somewhat more effectively.
- Maximum pressure reduction needed: Amlodipine delivers a few extra mm Hg of lowering, which can matter when you are far from target.
- Stroke and heart attack risk as the primary concern: Amlodipine-based regimens show stronger population-level protection against these events.
- Ankle swelling intolerance: Losartan avoids this problem entirely.
- Elderly or fall-prone patients: Losartan may carry less short-term fall risk.
For many patients, the answer ends up being both drugs together, since the combination leverages both mechanisms, produces larger blood pressure drops than either alone, and can mitigate the swelling side effect of amlodipine. If you’re currently on one and not at goal, adding the other is often the next step rather than switching.